🚀 VC round data is live in beta, check it out!
Orchestra BioMed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Orchestra BioMed and similar public comparables like Stratec, Profound Medical, Affluent Medical, TriSalus Life Sciences and more.
Orchestra BioMed Overview
About Orchestra BioMed
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Founded
2018
HQ
Employees
70
Website
Financials (LTM)
EV
$157M
Orchestra BioMed Financials
Orchestra BioMed reported last 12-month revenue of $25M and negative EBITDA of ($64M).
In the same LTM period, Orchestra BioMed generated $25M in gross profit, ($64M) in EBITDA losses, and had net loss of ($66M).
Revenue (LTM)
Orchestra BioMed P&L
In the most recent fiscal year, Orchestra BioMed reported revenue of $33M and EBITDA of ($51M).
Orchestra BioMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $25M | XXX | $33M | XXX | XXX | XXX |
| Gross Profit | $25M | XXX | $33M | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | ($64M) | XXX | ($51M) | XXX | XXX | XXX |
| EBITDA Margin | (258%) | XXX | (153%) | XXX | XXX | XXX |
| EBIT Margin | (262%) | XXX | (155%) | XXX | XXX | XXX |
| Net Profit | ($66M) | XXX | ($53M) | XXX | XXX | XXX |
| Net Margin | (267%) | XXX | (157%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Orchestra BioMed Stock Performance
Orchestra BioMed has current market cap of $248M, and enterprise value of $157M.
Market Cap Evolution
Orchestra BioMed's stock price is $4.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $157M | $248M | -1.1% | XXX | XXX | XXX | $-0.90 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrchestra BioMed Valuation Multiples
Orchestra BioMed trades at 6.3x EV/Revenue multiple, and (2.5x) EV/EBITDA.
EV / Revenue (LTM)
Orchestra BioMed Financial Valuation Multiples
As of April 11, 2026, Orchestra BioMed has market cap of $248M and EV of $157M.
Equity research analysts estimate Orchestra BioMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Orchestra BioMed has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $248M | XXX | $248M | XXX | XXX | XXX |
| EV (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | (2.5x) | XXX | (3.1x) | XXX | XXX | XXX |
| EV/EBIT | (2.4x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | 4.7x | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | (2.9x) | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Orchestra BioMed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Orchestra BioMed Margins & Growth Rates
Orchestra BioMed's revenue in the last 12 month declined by (94%).
Orchestra BioMed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.2M for the same period.
Orchestra BioMed's rule of 40 is (5900%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Orchestra BioMed's rule of X is (6043%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Orchestra BioMed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (94%) | XXX | (95%) | XXX | XXX | XXX |
| EBITDA Margin | (258%) | XXX | (153%) | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | 90% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (5900%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (6043%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 249% | XXX | 174% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 254% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Orchestra BioMed Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stratec | XXX | XXX | XXX | XXX | XXX | XXX |
| Profound Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Affluent Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| TriSalus Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Carlsmed | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orchestra BioMed M&A Activity
Orchestra BioMed acquired XXX companies to date.
Last acquisition by Orchestra BioMed was on XXXXXXXX, XXXXX. Orchestra BioMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Orchestra BioMed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOrchestra BioMed Investment Activity
Orchestra BioMed invested in XXX companies to date.
Orchestra BioMed made its latest investment on XXXXXXXX, XXXXX. Orchestra BioMed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Orchestra BioMed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Orchestra BioMed
| When was Orchestra BioMed founded? | Orchestra BioMed was founded in 2018. |
| Where is Orchestra BioMed headquartered? | Orchestra BioMed is headquartered in United States. |
| How many employees does Orchestra BioMed have? | As of today, Orchestra BioMed has over 70 employees. |
| Who is the CEO of Orchestra BioMed? | Orchestra BioMed's CEO is David P. Hochman. |
| Is Orchestra BioMed publicly listed? | Yes, Orchestra BioMed is a public company listed on Nasdaq. |
| What is the stock symbol of Orchestra BioMed? | Orchestra BioMed trades under OBIO ticker. |
| When did Orchestra BioMed go public? | Orchestra BioMed went public in 2023. |
| Who are competitors of Orchestra BioMed? | Orchestra BioMed main competitors are Stratec, Profound Medical, Affluent Medical, TriSalus Life Sciences. |
| What is the current market cap of Orchestra BioMed? | Orchestra BioMed's current market cap is $248M. |
| What is the current revenue of Orchestra BioMed? | Orchestra BioMed's last 12 months revenue is $25M. |
| What is the current revenue growth of Orchestra BioMed? | Orchestra BioMed revenue growth (NTM/LTM) is (94%). |
| What is the current EV/Revenue multiple of Orchestra BioMed? | Current revenue multiple of Orchestra BioMed is 6.3x. |
| Is Orchestra BioMed profitable? | No, Orchestra BioMed is not profitable. |
| What is the current EBITDA of Orchestra BioMed? | Orchestra BioMed has negative EBITDA and is not profitable. |
| What is Orchestra BioMed's EBITDA margin? | Orchestra BioMed's last 12 months EBITDA margin is (258%). |
| What is the current EV/EBITDA multiple of Orchestra BioMed? | Current EBITDA multiple of Orchestra BioMed is (2.5x). |
| What is the current FCF of Orchestra BioMed? | Orchestra BioMed's last 12 months FCF is ($55M). |
| What is Orchestra BioMed's FCF margin? | Orchestra BioMed's last 12 months FCF margin is (221%). |
| What is the current EV/FCF multiple of Orchestra BioMed? | Current FCF multiple of Orchestra BioMed is (2.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.